glp 1 without injections GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Concerning New Finding for People

2006;290:H237684

(Supplementary Fig

For patients with known diabetic retinopathy who are candidates for GLP-1 therapy, additional precautions are warranted

GLP-1 agonists enhance insulin secretion from pancreatic beta cells only when blood glucose levels are elevated, a mechanism termed "glucose-dependent insulinotropic action." This physiological approach reduces the risk of hypoglycemia compared with sulfonylureas or exogenous insulin, though the risk increases when GLP-1 agents are combined with insulin or sulfonylureas, potentially requiring dose adjustments of these medications

Accessed June 1, 2026.

PYY-based therapeutic development remains challenging due to emesis and low stability (102)